AbangeLabs35m ago
Sweden's Epidyolex decision is a useful read on indication-specific evidence standards and indirect-comparison limits. https://www.mattheneus.com/editorial/tlv-epidyolex-lgs-tsc-restricted-reimbursement-indirect-comparison-2026-05-26 #HTA #MAIC #EvidenceSynthesis #RegulatoryAffairs
Sweden restricts Epidyolex reimbursement after indication-specific evidence review

The Swedish Dental and Pharmaceutical Benefits Agency (TLV) added Epidyolex to high-cost protection with restrictions from 1 June 2026, using phase 3 randomised controlled trial (RCT) evidence and indirect comparison evidence by indication.

AbangeLabs Editorial
AbangeLabs3h ago
TLV's FILTERKANYL refusal shows the burden of proof for reimbursement price increases: product-level cost and margin evidence matters. https://www.mattheneus.com/editorial/tlv-filterkanyl-price-increase-refusal-cost-margin-evidence-2026-06-23 #HTA #EvidenceSynthesis #RegulatoryAffairs
Swedish agency rejects FILTERKANYL price increase after margin evidence gap

Sweden's Dental and Pharmaceutical Benefits Agency (TLV) refused a requested price increase for FILTERKANYL because the applicant did not provide product-level cost and profitability evidence needed to substantiate withdrawal risk.

AbangeLabs Editorial
AbangeLabs5d ago
Sweden limited Fabhalta reimbursement in C3G after weighing APPEAR-C3G proteinuria data against uncertain long-term model assumptions. https://www.mattheneus.com/editorial/tlv-fabhalta-iptacopan-c3g-limited-reimbursement-appear-c3g-2026-04-28 #HTA #EvidenceSynthesis #Pharma
Sweden limits Fabhalta reimbursement in complement 3 glomerulopathy after APPEAR-C3G review

Sweden's Dental and Pharmaceutical Benefits Agency (TLV) will reimburse Fabhalta for complement 3 glomerulopathy (C3G) with a narrow limitation, after weighing APPEAR-C3G proteinuria data against uncertain long-term model assumptions.

AbangeLabs Editorial
AbangeLabs5d ago
Sweden's TLV rejected a syringe reimbursement price increase because access-risk claims lacked quantified benefits-use evidence. https://www.mattheneus.com/editorial/tlv-fixed-needle-syringe-price-increase-rejection-low-benefits-use-2026-06-16 #HTA #EvidenceSynthesis #RegulatoryAffairs
Swedish Dental and Pharmaceutical Benefits Agency rejects fixed-needle syringe price increase

The Swedish Dental and Pharmaceutical Benefits Agency rejected Becton Dickinson Sweden ABs request for higher reimbursement prices for two fixed-needle 1 ml syringes. The decision turned on benefits-use data, not clinical efficacy, and shows how access-risk claims need quantified reimbursement evidence.

AbangeLabs Editorial
AbangeLabs6d ago
Sweden reimbursed Lyvdelzi after reviewing a MAIC-based comparison in PBC, a useful HTA signal for indirect evidence strategy. https://www.mattheneus.com/editorial/tlv-lyvdelzi-seladelpar-pbc-general-reimbursement-maic-response-elative-2026-01-27 #HTA #MAIC #EvidenceSynthesis #Pharma
Sweden reimburses Lyvdelzi for primary biliary cholangitis after matched indirect comparison against Iqirvo

Sweden's Dental and Pharmaceutical Benefits Agency (TLV) has granted general reimbursement for seladelpar (Lyvdelzi) in primary biliary cholangitis (PBC), a health technology assessment (HTA) decision that reviewed RESPONSE and ELATIVE phase III evidence through a matching-adjusted indirect comparison (MAIC) and a cost comparison versus Iqirvo.

AbangeLabs Editorial
AbangeLabsJun 23
A failed gabapentin oral-solution restriction in Sweden shows how reimbursement can turn on unmet-evidence claims, comparator logic, and subgroup justification. https://www.mattheneus.com/editorial/tlv-neurisol-gabapentin-oral-solution-non-reimbursement-restriction-evidence-gap-2026-02-24 #HTA #EvidenceSynthesis #Pharma
Sweden rejects Neurisol reimbursement after gabapentin oral-solution restriction fails

Sweden's Dental and Pharmaceutical Benefits Agency (TLV) rejected reimbursement for Neurisol, an oral gabapentin solution, after concluding that the proposed limited-use group was not clinically appropriate and that the company had not submitted health economic evidence for general reimbursement.

AbangeLabs Editorial
AbangeLabsJun 23
Comparator choice is now part of the reimbursement evidence file, not a late pricing detail. Sweden's TLV guidance shows why HTA teams need traceable rationale from protocol to submission. https://www.mattheneus.com/editorial/tlv-subvention-pricing-guidelines-evidence-file-2026-06-16 #HTA #EvidenceSynthesis #RegulatoryAffairs
Sweden's pricing guidelines put comparator choice into the reimbursement file

Sweden's new medicine subsidy and pricing guidelines give market access teams a practical checkpoint for comparator rationale, health economic modelling, rare-disease evidence, and budget-impact documentation before October 2026 submissions.

AbangeLabs Editorial
Christel HellbergJun 23
I’ve worked with systematic reviews for 14+ years, but have only recently moved into agronomy and environmental science.
And one thing keeps surprising me…
#SystematicReview #SysRev #EvidenceSynthesis
AbangeLabsJun 23
Value-based healthcare claims are only as strong as the implementation-cost ledger behind them: staffing, throughput, data burden, and budget impact. https://www.mattheneus.com/editorial/value-based-healthcare-implementation-cost-ledger-market-access-2026-06-17 #HTA #HealthEconomics #EvidenceSynthesis
Value-based healthcare needs an implementation-cost ledger before reimbursement

Value-based healthcare is moving from aspiration to reimbursement evidence. Health technology assessment and market access teams should document implementation cost, throughput, staffing, data burden, and budget impact before value claims are tested by payers.

AbangeLabs Editorial
AbangeLabsJun 13
Sweden's TLV reimbursed Saphnelo after accepting comparable effect versus Benlysta and equal annual medicine cost, a useful signal for HTA evidence strategy. https://www.mattheneus.com/editorial/tlv-saphnelo-sle-general-reimbursement-indirect-comparison-cost-parity-2026-05-26 #HTA #EvidenceSynthesis #HealthEconomics
Swedish Dental and Pharmaceutical Benefits Agency reimburses Saphnelo after Benlysta cost-parity review

Sweden has reimbursed Saphnelo for systemic lupus erythematosus after accepting a comparable-effect case built from TULIP-SC, administration-form bridging, indirect comparison, and cost parity versus Benlysta.

AbangeLabs Editorial